A recent meta-analysis17 investigated the predictive role of KRAS-mutations in 519 patients with previously treated NSCLC included in trials with nivolumab or atezolizumab (CheckMate 057, OAK and POPLAR studies). This evidence concerns the gene KRAS and non-small cell lung carcinoma.